60NYT > GlaxoSmithKline PLC.topics.nytimes.com/top/news/business/companies/glaxosmithkline_plc/index.html?8qaNews about GlaxoSmithKline PLC., including commentary and archival articles published in The New York Times.Copyright 2014 The New York Times Companyen-usTue 31 Mar 2015 19:01:34 -0400http://static01.nyt.com/images/section/NytSectionHeader.gifNYThttp://www.nytimes.comEbola Vaccines Pass Initial Safety Testshttp://www.nytimes.com/2015/03/27/world/africa/ebola-vaccines-pass-initial-safety-tests.html?partner=rssnyt&emc=rssTwo experimental Ebola vaccines “appear to be safe” partway through a clinical trial being conducted in Liberia, the National Institutes of Health said Thursday.By REUTERSFri, 27 Mar 2015 00:00:00 -0400http://www.nytimes.com/2015/03/27/world/africa/ebola-vaccines-pass-initial-safety-tests.html?partner=rssnyt&emc=rssTrial of 2 Ebola Vaccines’ Effectiveness Is Announcedhttp://www.nytimes.com/2015/01/23/business/international/trial-of-2-ebola-vaccines-effectiveness-is-announced.html?partner=rssnyt&emc=rssTests of drugs developed by GlaxoSmithKline and Merck are expected to begin in Liberia in two weeks, federal officials said.By ANDREW POLLACKFri, 23 Jan 2015 00:00:00 -0500http://www.nytimes.com/2015/01/23/business/international/trial-of-2-ebola-vaccines-effectiveness-is-announced.html?partner=rssnyt&emc=rssIn Africa, a Decline in New Ebola Cases Complicates Vaccine Developmenthttp://www.nytimes.com/2015/01/10/health/ebbing-of-ebola-complicates-testing-of-vaccines.html?partner=rssnyt&emc=rss<a href="http://www.nytimes.com/2015/01/10/health/ebbing-of-ebola-complicates-testing-of-vaccines.html?partner=rssnyt&emc=rss"><img src="http://static01.nyt.com/images/2015/01/10/world/VACCINE/VACCINE-thumbStandard.jpg" border="0" height="75" width="75" hspace="4" align="left"/></a>Clinical trials in Africa are being pushed by a sense of urgency as fewer new cases occur, making it more difficult to determine how effective the drugs are.By ANDREW POLLACKSat, 10 Jan 2015 00:00:00 -0500http://www.nytimes.com/2015/01/10/health/ebbing-of-ebola-complicates-testing-of-vaccines.html?partner=rssnyt&emc=rssFrom Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs http://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html?partner=rssnyt&emc=rss<a href="http://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html?partner=rssnyt&emc=rss"><img src="http://static01.nyt.com/images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg" border="0" height="75" width="75" hspace="4" align="left"/></a>In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus.By ANDREW POLLACKSat, 10 Jan 2015 00:00:00 -0500http://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html?partner=rssnyt&emc=rssHospital Pauses Test of an Ebola Vaccine Licensed to Merckhttp://www.nytimes.com/2014/12/12/business/geneva-hospital-pauses-test-of-an-ebola-vaccine.html?partner=rssnyt&emc=rss<a href="http://www.nytimes.com/2014/12/12/business/geneva-hospital-pauses-test-of-an-ebola-vaccine.html?partner=rssnyt&emc=rss"><img src="http://static01.nyt.com/images/2014/12/12/business/Vaccine/Vaccine-thumbStandard.jpg" border="0" height="75" width="75" hspace="4" align="left"/></a>The hospital said it would halt injections of a vaccine licensed to Merck until next month, after some test subjects reported mild joint pain.By ANDREW POLLACKFri, 12 Dec 2014 00:00:00 -0500http://www.nytimes.com/2014/12/12/business/geneva-hospital-pauses-test-of-an-ebola-vaccine.html?partner=rssnyt&emc=rssGlaxo Plans Hundreds of Layoffs at U.S. Unit http://www.nytimes.com/2014/12/05/business/glaxo-plans-hundreds-of-layoffs-at-us-unit.html?partner=rssnyt&emc=rssGlaxoSmithKline is making changes worldwide that are meant to produce about $1.6 billion in annual savings within about three years —By THE ASSOCIATED PRESSFri, 05 Dec 2014 00:00:00 -0500http://www.nytimes.com/2014/12/05/business/glaxo-plans-hundreds-of-layoffs-at-us-unit.html?partner=rssnyt&emc=rssGlaxoSmithKline Leads In Getting Drugs to Poorhttp://www.nytimes.com/2014/12/02/science/glaxosmithkline-leads-in-getting-drugs-to-poor.html?partner=rssnyt&emc=rssEarly editions of the Access to Medicine Index focused on infectious and tropical diseases, but the list has been refined to include access to drugs to mental illnesses.By DONALD G. McNEIL JrTue, 02 Dec 2014 00:00:00 -0500http://www.nytimes.com/2014/12/02/science/glaxosmithkline-leads-in-getting-drugs-to-poor.html?partner=rssnyt&emc=rssHealth Officials Expect to Start Vaccine Trials in West Africa as Early as December http://www.nytimes.com/2014/10/25/business/ebola-vaccine-trials-planned-for-december.html?partner=rssnyt&emc=rssParticipants in Liberia and Sierra Leone would receive experimental vaccines that could lead to mass inoculations in 2015, health officials said Friday.By ANDREW POLLACKSat, 25 Oct 2014 00:00:00 -0400http://www.nytimes.com/2014/10/25/business/ebola-vaccine-trials-planned-for-december.html?partner=rssnyt&emc=rssTesting for Ebola Vaccines to Start Soon, W.H.O. Sayshttp://www.nytimes.com/2014/10/22/business/testing-for-ebola-vaccines-to-start-soon-who-says.html?partner=rssnyt&emc=rss<a href="http://www.nytimes.com/2014/10/22/business/testing-for-ebola-vaccines-to-start-soon-who-says.html?partner=rssnyt&emc=rss"><img src="http://static01.nyt.com/images/2014/10/22/business/Drug/Drug-thumbStandard.jpg" border="0" height="75" width="75" hspace="4" align="left"/></a>The plans signify that a response to the Ebola outbreak is finally gathering steam, but it is still unclear if any of these vaccines will work.By ANDREW POLLACKWed, 22 Oct 2014 00:00:00 -0400http://www.nytimes.com/2014/10/22/business/testing-for-ebola-vaccines-to-start-soon-who-says.html?partner=rssnyt&emc=rssR.B.S. Chairman to Step Downhttp://dealbook.nytimes.com/2014/09/25/r-b-s-chairman-to-step-down-and-join-glaxosmithkline/?partner=rssnyt&emc=rssPhilip Hampton, who has served as chairman or R.B.S. since 2009, is expected to join the board of the drug maker GlaxoSmithKline in January.By CHAD BRAYThu, 25 Sep 2014 04:38:13 -0400http://dealbook.nytimes.com/2014/09/25/r-b-s-chairman-to-step-down-and-join-glaxosmithkline/?partner=rssnyt&emc=rss